+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Type (Powder Colloidal Bismuth Pectin, Granular Colloidal Bismuth Pectin), By Application (Stomach Ulcer Treatment, Gastritis Treatment, Other Gastrointestinal Conditions), By End User (Hospitals, Clinics, Retail Pharmacies), By Formulation Type (Single-Dose Sachets, Multi-Dose Bottles, Custom Compounded Preparations), By Therapeutic Approach (First-Line Therapy, Adjunct Therapy, Rescue Therapy), and Regional Forecast, 2026-2034
The global colloidal bismuth pectin for suspension market was valued at USD 310.0 million in 2025 and is estimated at USD 327.0 million in 2026. The market is projected to reach USD 500.6 million by 2034, representing a 5.5% CAGR during 2026–2034.
Colloidal bismuth pectin for suspension is a bismuth-based gastrointestinal medicine used in China and selected Asian markets for mucosal protection and as a component of Helicobacter pylori eradication regimens. Commercial products are supplied in powder or granular forms for preparation as a suspension and are distributed through hospital, clinic and retail channels.
The strongest evidence base is linked to H. pylori combination therapy rather than stand-alone ulcer treatment. A multicenter randomized trial of 339 patients found a 90.5% intention-to-treat cure rate with a 14-day colloidal bismuth pectin quadruple regimen and showed non-inferiority to bismuth potassium citrate quadruple therapy. Current North American guidelines recommend optimized bismuth quadruple therapy, although the named bismuth salts in the ACG regimen are bismuth subcitrate or subsalicylate rather than colloidal bismuth pectin.
Clinical research in China continues to test CBP inside newer acid-suppression regimens. A 2026 randomized study enrolled 579 H. pylori-positive patients and included a vonoprazan, amoxicillin, doxycycline and CBP arm, while another 2026 trial compared tegoprazan-amoxicillin dual therapy with a CBP-containing quadruple regimen. These studies support ongoing demand for CBP as an adjunct within evolving eradication strategies.
Source: American College of Gastroenterology; CBP non-inferiority trial; 2026 vonoprazan trial; 2026 tegoprazan trial.
The study defines the global colloidal bismuth pectin for suspension market market by the equipment, application, end-user and technology boundaries listed below. The scope is structured to keep market sizing consistent with the commercial systems and services included in the syndicated study.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million |
| By Type | Powder Colloidal Bismuth Pectin; Granular Colloidal Bismuth Pectin |
| By Application | Stomach Ulcer Treatment; Gastritis Treatment; Other Gastrointestinal Conditions |
| By End User | Hospitals; Clinics; Retail Pharmacies |
| By Formulation Type | Single-Dose Sachets; Multi-Dose Bottles; Custom Compounded Preparations |
| By Therapeutic Approach | First-Line Therapy; Adjunct Therapy; Rescue Therapy |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | China; Japan; South Korea; India; United States; Canada; Germany; United Kingdom; France; Brazil; Mexico; GCC countries and other relevant markets |
| Key Market Players | Shanxi Zhendong Pharmaceutical; Hunan Warrant Pharmaceutical; Zhejiang Anglikang Pharmaceutical; Heilongjiang Jiangshi Pharmaceutical; Shanxi PUDE Pharmaceutical; Hunan Jiudian Pharmaceutical; Heilongjiang Zhonggui Pharmaceutical; Inner Mongolia Huazhong Pharmaceutical; Guizhou Bailing Group Pharmaceutical; Jilin Connell Pharmaceutical; Shandong Xinhua Pharmaceutical; Zhejiang Medicine Co., Ltd.; Jiangsu Nhwa Pharmaceutical; Guangxi Wuzhou Zhongheng Group; Beijing Double-Crane Pharmaceutical |
The market includes colloidal bismuth pectin products formulated for oral suspension and used in gastrointestinal treatment, including H. pylori-related regimens, gastritis and ulcer-care pathways where the product is prescribed or dispensed. Powder, granular, sachet, bottle and compounded formats are included when colloidal bismuth pectin is the principal bismuth ingredient.
Other bismuth compounds such as bismuth subsalicylate and bismuth subcitrate are excluded from the core revenue boundary unless used as clinical comparators. Proton pump inhibitors, potassium-competitive acid blockers and antibiotics are not included in market revenue even when administered in the same eradication regimen.
The 2024 American College of Gastroenterology guideline recommends optimized bismuth quadruple therapy for 14 days in treatment-na - ve patients. Although the guideline specifies bismuth subcitrate or subsalicylate, the continued central role of bismuth-containing regimens supports the broader therapeutic rationale for CBP in markets where it is approved and prescribed.
A multicenter trial randomized 339 patients and reported a 90.5% intention-to-treat cure rate with CBP quadruple therapy. The regimen was non-inferior to bismuth potassium citrate quadruple therapy, providing a specific clinical evidence base for CBP use in China.
Rising clarithromycin and levofloxacin resistance has reduced confidence in empiric regimens that rely on those antibiotics without susceptibility information. This supports continued use and research of bismuth-containing strategies, including CBP-based combinations in regional practice.
CBP is much more established in China and selected Asian markets than in North America or Western Europe, where other bismuth salts dominate guideline language and product availability. This makes geographic expansion dependent on local registration, physician familiarity and comparative evidence.
H. pylori eradication regimens involve multiple medicines and frequent dosing. Single-dose sachets, stable granules and patient-friendly suspension preparation can therefore create value by simplifying administration within otherwise complex combination therapy.
Source: ACG guideline; CBP trial.
Vonoprazan and tegoprazan provide stronger and more sustained acid suppression than conventional proton pump inhibitors. 2026 randomized studies in China incorporated CBP into PCAB-based quadruple regimens, creating new opportunities for the product within modern eradication strategies.
A 579-patient 2026 trial compared a CBP-containing vonoprazan quadruple regimen with vonoprazan-amoxicillin and vonoprazan-doxycycline dual therapy. This reflects a competitive shift toward reducing regimen complexity while preserving eradication efficacy.
Commercial value increasingly depends on how the bismuth product performs inside a full eradication regimen rather than on mucosal-protection claims alone. Comparative trials, antibiotic-resistance patterns and adherence therefore influence physician selection.
Sachets provide dose consistency and portability for suspension products and can reduce handling compared with repeated measurement from multi-dose containers. The format is particularly relevant where CBP is used several times daily as part of a multidrug course.
The supplier base is concentrated in China, where CBP is established in gastrointestinal care. Domestic manufacturing scale supports regional competition while creating an export opportunity where registration and clinical acceptance permit.
Source: 2026 vonoprazan trial; 2026 tegoprazan trial; ACG guideline.
Commercial positioning depends on how colloidal bismuth pectin is formulated, packaged and incorporated into gastrointestinal treatment. The product competes both as a mucosal-protective bismuth medicine and as one component of multidrug H. pylori eradication therapy.
Dry formulations are reconstituted or dispersed for oral administration. Powder provides established manufacturing and dosing flexibility, while granular products compete on flow, stability and preparation convenience.
CBP can be administered with acid suppression and antibiotics in H. pylori eradication regimens. Clinical value depends on the complete regimen, local resistance patterns and patient adherence.
Single-dose sachets support accurate dosing and portability, while multi-dose containers can reduce packaging cost where repeated administration is routine.
Recent Chinese trials combine CBP with vonoprazan or tegoprazan, showing how newer acid blockers can alter regimen design without removing the role of bismuth.
Source: CBP trial; 2026 vonoprazan trial.
By type, the market is segmented into powder colloidal bismuth pectin and granular colloidal bismuth pectin. Powder products form the established commercial base, while granular formats compete through handling, stability and reconstitution characteristics.
Powder CBP is the leading type in the syndicated scope. It supports flexible suspension preparation and established manufacturing workflows and remains widely used across hospital and retail channels in China.
Granular products target improved handling and dose preparation. Their commercial opportunity depends on stability, dispersibility and the ability to provide a consistent suspension while maintaining acceptable production economics.
Powder formulations are expected to retain the largest revenue contribution through 2034, while granular products can gain selective share where improved handling and stability provide a meaningful dispensing advantage.
By application, the market is analyzed across stomach ulcer treatment, gastritis treatment and other gastrointestinal conditions. Demand is closely linked to H. pylori management and regional prescribing patterns rather than to ulcer symptoms alone.
CBP is used in ulcer-care pathways where mucosal protection and H. pylori eradication are clinically relevant. The segment benefits from continued use of bismuth-containing therapy in ulcer patients with confirmed infection.
Gastritis represents an important application in Asian practice, particularly where H. pylori is identified and a bismuth-containing regimen is selected. Diagnosis and eradication testing influence treatment volume.
Other uses include selected dyspeptic or mucosal disorders where clinicians prescribe bismuth therapy according to local practice and labeling. This segment is smaller and more heterogeneous.
H. pylori-related gastritis and ulcer treatment will remain the principal commercial demand base, while other gastrointestinal use is expected to remain dependent on local physician practice and product labeling.
By end user, demand is segmented across hospitals, clinics and retail pharmacies. The channel mix reflects where H. pylori is diagnosed, where multidrug therapy is initiated and how suspension products are dispensed for outpatient completion.
Hospitals represent the leading end-user segment in the syndicated scope because gastroenterology services, diagnostic testing and complex eradication therapy are concentrated in institutional care. Hospital formularies can materially influence brand selection.
Gastroenterology and primary-care clinics initiate treatment for gastritis, ulcer disease and H. pylori infection and generate recurring prescriptions for outpatient completion.
Retail pharmacies support outpatient access and repeat dispensing. Their role grows where prescriptions are filled outside hospital pharmacies and where single-dose sachets improve convenience.
Hospitals are expected to remain the primary institutional demand center, while clinics and retail pharmacies continue to support outpatient treatment completion and broader product availability.
By formulation type, the market is segmented into single-dose sachets, multi-dose bottles and custom compounded preparations. Packaging influences dosing accuracy, storage, contamination risk and patient convenience.
Sachets provide a premeasured dose and are well suited to outpatient multidrug regimens. They can simplify administration and reduce measurement variability when the product is taken repeatedly during eradication therapy.
Multi-dose containers can reduce unit packaging cost and remain practical where the suspension is prepared or dispensed in larger quantities. Accurate measurement and storage instructions are important to consistent use.
Compounded preparations address situations where standard commercial packaging does not meet a specific dosing or administration need. Their role is limited by local pharmacy practice and quality-control requirements.
Single-dose sachets are positioned for above-average adoption where convenience and dose control are valued, while multi-dose bottles remain important for cost-sensitive and established dispensing workflows.
By therapeutic approach, CBP use is analyzed across first-line therapy, adjunct therapy and rescue therapy. Its role depends on the accompanying acid suppressant and antibiotics, prior treatment history and regional resistance patterns.
CBP can be used in first-line bismuth-containing eradication regimens in markets where it is approved and familiar. Comparative clinical evidence supports its use as the bismuth component of a 14-day quadruple regimen in China.
Adjunct use reflects CBP being layered with acid suppression and antibiotics rather than acting as the sole therapeutic driver. This is commercially important because regimen design can evolve while retaining a bismuth component.
Rescue use arises after prior eradication failure or where resistance concerns narrow other options. The exact regimen depends on local guidelines, susceptibility information and prior antibiotic exposure.
Adjunct and regimen-based use is expected to remain central to market value because CBP is usually commercialized as one component of a broader gastrointestinal treatment strategy rather than as a stand-alone eradication therapy.
Regional demand is highly concentrated because colloidal bismuth pectin is established in China and selected Asian markets but is not the dominant bismuth formulation in Western treatment guidelines. Asia-Pacific is therefore the largest regional market.
China anchors global CBP demand through local manufacturing, established prescribing and direct clinical research on CBP-containing H. pylori regimens. Other Asian markets provide selective opportunities depending on registration and physician familiarity.
North American H. pylori guidelines strongly support bismuth quadruple therapy, but use bismuth subcitrate or subsalicylate rather than CBP. Direct CBP market penetration is therefore limited relative to Asia-Pacific.
European gastrointestinal practice uses bismuth-containing eradication strategies in selected settings, but CBP-specific availability is narrower than in China. Regulatory access remains a prerequisite to expansion.
H. pylori burden creates a clinical rationale for effective eradication regimens, but CBP adoption is constrained by product availability and preference for locally established bismuth salts.
Demand remains limited and opportunity is linked to registration, specialist gastroenterology access and the availability of CBP-containing products within local formularies.
Source: ACG guideline; CBP trial.
CBP commercialization depends on local pharmaceutical approval, bismuth exposure limits, formulation quality and evidence supporting its role within combination therapy. The global guideline environment is not uniform, so regional access cannot be inferred from bismuth use generally.
| Framework / Event | Requirement or Development | Commercial Relevance |
|---|---|---|
| Guideline treatment context | The 2024 ACG guideline recommends optimized 14-day bismuth quadruple therapy but specifies bismuth subcitrate or subsalicylate. | Supports the bismuth class while illustrating that CBP-specific access is region-dependent. |
| Direct comparative evidence | The 339-patient randomized trial found CBP quadruple therapy non-inferior to bismuth potassium citrate quadruple therapy in China. | Provides product-specific clinical support within a defined regional treatment setting. |
| Test-of-cure requirements | ACG recommends confirming eradication at least four weeks after therapy and withholding bismuth and antibiotics for four weeks before testing. | Reinforces structured follow-up and may influence treatment adherence programs. |
| Combination-regimen complexity | CBP is commonly used with acid suppression and antibiotics, so safety and compliance depend on the complete regimen. | Makes packaging, counseling and clear dosing instructions commercially important. |
Source: ACG guideline; CBP randomized trial.
The competitive landscape is regionally concentrated and led by Chinese pharmaceutical manufacturers. Competition centers on formulation quality, production reliability, hospital tender access, provincial and retail distribution, packaging formats and physician familiarity with CBP-containing regimens.
Shanxi Zhendong Pharmaceutical, Hunan Warrant Pharmaceutical and other established manufacturers benefit from domestic distribution and familiarity within gastrointestinal treatment channels.
Zhejiang Anglikang, Hunan Jiudian, Shandong Xinhua and other suppliers compete through formulation breadth, manufacturing economics and access to regional hospital and pharmacy networks.
Manufacturers can differentiate through clinical support, dosing convenience and alignment with evolving PCAB-based eradication strategies rather than relying only on generic mucosal-protection positioning.
Source: CBP clinical trial; 2026 vonoprazan trial.
2026: A prospective multicenter randomized trial enrolled 579 H. pylori-positive patients and compared vonoprazan-amoxicillin or vonoprazan-doxycycline dual therapy with a four-drug regimen containing colloidal bismuth pectin 300 mg twice daily.
2026: A separate 400-patient randomized trial compared tegoprazan-amoxicillin dual therapy with a tegoprazan-based quadruple regimen containing colloidal bismuth pectin, extending evidence for CBP within newer PCAB-based treatment strategies.
2024 guideline cycle: The American College of Gastroenterology reinforced optimized 14-day bismuth quadruple therapy as a recommended first-line treatment strategy in North America, increasing attention to bismuth-containing eradication approaches while maintaining salt-specific regional differences.
Source: 2026 vonoprazan study; 2026 tegoprazan study; ACG guideline.
The global colloidal bismuth pectin for suspension market market is projected to grow from USD 327.0 million in 2026 to USD 500.6 million by 2034, at a 5.5% CAGR during 2026–2034. Growth is expected to remain concentrated in Asia-Pacific, where CBP has established manufacturing and clinical use. Market expansion will depend on H. pylori treatment volumes, packaging convenience, evidence for newer combination regimens and the product’s ability to maintain relevance as simplified PCAB-based therapies develop.
| Forecast Variable | Current Evidence / Starting Point | Expected Effect Through 2034 |
|---|---|---|
| H. pylori treatment | Bismuth-containing therapy remains an important eradication strategy. | Sustains a clinical role for CBP in markets where it is approved and prescribed. |
| Comparative evidence | Randomized trials provide direct CBP efficacy data in Chinese patients. | Strengthens physician confidence in product-specific use rather than relying only on class evidence. |
| PCAB combinations | 2026 studies include CBP with vonoprazan and tegoprazan regimens. | Creates opportunities within evolving acid-suppression strategies. |
| Regional concentration | China remains the principal production and clinical-use base. | Supports scale but limits immediate global diversification. |
| Packaging innovation | Sachets and stable granular formats can simplify outpatient administration. | Provides a practical route to differentiation in a mature active-ingredient category. |
The study is structured to support strategy, market-entry assessment, portfolio planning, competitive benchmarking and commercial opportunity analysis across the global colloidal bismuth pectin for suspension market landscape.
24LifeScience develops colloidal bismuth pectin for suspension market market estimates using a combination of bottom-up and top-down assessment. Bottom-up work reviews relevant manufacturers, product portfolios, geographic presence, installation or utilization patterns, commercial channels and pricing structure. Top-down work evaluates the addressable testing or diagnostic environment, installed capacity, procedure or production demand, replacement and upgrade cycles, and regional access conditions.
Primary research is used to validate market structure, purchasing criteria, technology adoption, competitive positioning and operating constraints where available. Secondary research prioritizes regulators, government and public-health agencies, recognized standards, peer-reviewed or professional evidence, and company filings or official product communications. Clinical evidence is checked against the American College of Gastroenterology and peer-reviewed PubMed-indexed randomized trials. CBP-specific claims are distinguished from evidence on other bismuth salts, and unsupported global-treatment assumptions are excluded.
Forecasts incorporate the 2025 market base, 2026 estimated conditions, technology and regulatory developments, replacement or expansion demand, regional investment, pricing pressure, service requirements and competitive intensity. High-impact assumptions are cross-checked against authoritative evidence before publication.
The market was valued at USD 310.0 million in 2025 and is estimated at USD 327.0 million in 2026. It is projected to reach USD 500.6 million by 2034 at a 5.5% CAGR during 2026–2034.
Asia-Pacific is the largest regional market, with China serving as the principal manufacturing and clinical-use base for colloidal bismuth pectin.
Powder colloidal bismuth pectin is the leading type in the syndicated scope, supported by established suspension-preparation and manufacturing workflows.
CBP is used in gastrointestinal care and can serve as the bismuth component of multidrug H. pylori eradication regimens in markets where it is approved and prescribed.
A 339-patient multicenter randomized trial reported a 90.5% intention-to-treat cure rate with CBP quadruple therapy and found it non-inferior to bismuth potassium citrate quadruple therapy.
The 2024 ACG guideline recommends optimized bismuth quadruple therapy but names bismuth subcitrate or bismuth subsalicylate, not colloidal bismuth pectin.
2026 randomized studies in China are evaluating CBP within vonoprazan- and tegoprazan-based regimens, linking the product to newer potassium-competitive acid blocker strategies.
The report profiles Shanxi Zhendong, Hunan Warrant, Zhejiang Anglikang, Hunan Jiudian, Shandong Xinhua and other Chinese pharmaceutical manufacturers.
The standardized forecast period is 2026–2034, with 2025 as the base year and 2026 as the estimated year.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.
